Ionis Pharma (IONS) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall St set for steady open as oil jumps ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
- Deutsche Bank Upgrades AST Spacemobile (ASTS) to Buy
Ionis' 2015 Financial Results Outperform Projections
February 25, 2016 8:30 AM ESTCARLSBAD, Calif., Feb. 25, 2016 /PRNewswire/ --Â Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported it ended the year in a strong financial position, significantly outperforming its guidance for both pro forma net operating loss (NOL) and cash.
"We have a pipeline of drugs with the potential to change the lives of patients with many different diseases. In 2015, we completed target enrollment in three... More



